|1.||Sun, Yu-Nien: 8 articles (06/2015 - 07/2009)|
|2.||Rasmussen, Erik: 4 articles (06/2015 - 07/2009)|
|3.||Wu, Benjamin: 3 articles (10/2015 - 04/2012)|
|4.||Vergote, Ignace B: 3 articles (09/2013 - 02/2012)|
|5.||Karlan, Beth Y: 3 articles (09/2013 - 02/2012)|
|6.||Weinreich, David M: 3 articles (01/2013 - 02/2012)|
|7.||Oliner, Jonathan D: 3 articles (04/2012 - 07/2009)|
|8.||Navale, Lynn: 2 articles (10/2015 - 05/2012)|
|9.||Ravaud, Alain: 2 articles (10/2015 - 12/2012)|
|10.||Tomczak, Piotr: 2 articles (10/2015 - 12/2012)|
08/01/2010 - "If safe and effective, AMG-386 could be an exciting addition to other antiangiogenic therapies in solid tumors."
07/20/2009 - "This first-in-human study evaluated the safety, pharmacokinetics (PK), pharmacodynamics, and antitumor activity of AMG 386 in adults with advanced solid tumors. "
07/20/2009 - "AMG 386 also appeared to impact tumor vascularity and showed antitumor activity in this patient population."
07/20/2009 - "One occurrence of dose-limiting toxicity was seen at 30 mg/kg: respiratory arrest, which likely was caused by tumor burden that was possibly related to AMG 386. "
07/20/2009 - "Safety, pharmacokinetics, and antitumor activity of AMG 386, a selective angiopoietin inhibitor, in adult patients with advanced solid tumors."
|2.||Ovarian Neoplasms (Ovarian Cancer)
05/01/2012 - "Increased exposure to AMG 386 was associated with improved clinical outcomes in recurrent ovarian cancer, supporting the evaluation of a higher dose in future studies."
05/01/2012 - "To characterize exposure-response relationships of AMG 386 in a phase 2 study in advanced ovarian cancer for the facilitation of dose selection in future studies. "
02/01/2011 - "Preclinical and clinical studies for AMG 386 are summarized, highlighting data pertaining to ovarian cancer. "
06/01/2015 - "The aim of this review is to summarize the recent researches and clinical progresses of AMG 386 as a novel target agent in ovarian cancer. "
06/01/2015 - "Advances in anti-angiogenic agents for ovarian cancer treatment: The role of trebananib (AMG 386)."
|3.||Renal Cell Carcinoma (Grawitz Tumor)
10/20/2015 - "Trebananib (AMG 386) in Combination With Sunitinib in Patients With Metastatic Renal Cell Cancer: An Open-Label, Multicenter, Phase II Study."
08/01/2010 - "Phase II trials of AMG-386 in combination with chemotherapy were ongoing in a variety of solid tumors, including breast, ovarian, colorectal, gastric and renal cell cancers. "
11/01/2012 - "Here we review the adverse-event profiles of targeted therapies being developed, including axitinib, tivozanib, dovitinib, AS1411, vorinostat, AMG386, BMS-936558, carfilzomib, IMA901, and AGS-003, for renal cell carcinoma."
09/01/2015 - "A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial."
12/15/2012 - "AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study."
01/01/2011 - "However, women who received low-dose AMG 386 had a third less risk of disease progression than those who received placebo (HR 0.57, 95% CI 0.36 to 0.91; P = 0.02). "
06/01/2010 - "Three cohorts of patients (F, n = 6; C/P, n = 8; D, n = 12) received one full cycle of chemotherapy alone during the pretreatment phase, followed by administration of AMG 386 10 mg/kg i.v. weekly in combination with chemotherapy until disease progression or intolerance. "
01/01/2011 - "There is also some evidence from a single trial that low-dose AMG 386 may reduce the risk of disease progression in women with recurrent ovarian cancer. "
12/15/2012 - "Among 30 patients in arm C who had disease progression and subsequently received open-label AMG 386 at 10 mg/kg qw, the objective response rate was 3% (95% CI, 0%-17%). "
12/15/2012 - "Patients in arm C could receive open-label AMG 386 at 10 mg/kg qw plus sorafenib following disease progression. "
|1.||TIE-2 Receptor (Receptor, TIE 2)
|9.||Epidermal Growth Factor Receptor (EGF Receptor)
|10.||Protein-Tyrosine Kinases (Tyrosine Kinase)
|1.||Drug Therapy (Chemotherapy)
|2.||Heterologous Transplantation (Xenotransplantation)